

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Herr Amy E.</u>  (Last) (First) (Middle) <u>614 MCKINLEY PLACE NE</u>  (Street) <u>MINNEAPOLIS MN 55413</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/01/2025</u>	3. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [ TECH ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,860	I	By significant other

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)	08/08/2025	Common Stock	3,256	44.33	I	By significant other
Stock Option (Right to Buy)	(1)	08/07/2026	Common Stock	6,636	47.6	I	By significant other
Stock Option (Right to Buy)	(1)	08/05/2027	Common Stock	4,472	66.97	I	By significant other
Stock Option (Right to Buy)	(2)	08/06/2028	Common Stock	2,076	120.46	I	By significant other
Stock Option (Right to Buy)	(3)	08/15/2029	Common Stock	2,104	94.52	I	By significant other
Stock Option (Right to Buy)	(4)	08/15/2030	Common Stock	1,084	84.61	I	By significant other
Stock Option (Right to Buy)	(5)	08/15/2034	Common Stock	1,468	74.91	I	By significant other
Restricted Stock Units	(6)	(6)	Common Stock	237	(7)	I	By significant other
Restricted Stock Units	(8)	(8)	Common Stock	480	(7)	I	By significant other

**Explanation of Responses:**

- Fully vested.
- 520 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2025; and 516 shares vest on 8/6/2024.
- 528 shares vest on 8/15/2023 and 8/15/2025; 524 shares vest on 8/15/2024 and 8/15/2026.
- 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.

Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power 02/07/2025 of Attorney filed herewith.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Shane Bohnen, James Hippel, Anna Weispfenning, Alyssa Mason, Melodie R. Rose, Andrew Nick, Liz Dunshee or either of them acting alone, the undersigned's true and lawful attorneys-in-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 3, Forms 4 and Forms 5 relating to beneficial ownership of securities of Bio-Techne Corporation (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 31st day of January, 2025.

/s/ Amy E. Herr  
Amy E. Herr